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bstract
Patients with breast cancer face substantial challenges to bone health from bone metastases, as well as from chemotherapy and endocrine
herapies that generally elicit disease control at the cost of increased bone turnover. Consequently, maintaining bone health is of critical
mportance for these patients. Recently reported results from BOLERO-2 showed significant clinical benefits with adding everolimus to
xemestane therapy in postmenopausal women with estrogen-receptor-positive breast cancer recurring or progressing despite nonsteroidal
romatase inhibitor therapy. Moreover, exploratory analyses from BOLERO-2 showed that adding everolimus may have beneficial effects on
one turnover and progressive disease in bone in this patient population. 
nhibition was associated with decreased osteoclast survival and activity.
ffects of estrogen suppression on bone health. This review discusses the ef
 2013 The Authors. Published by Elsevier Ireland Ltd. 
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Open access undThese results are supported by preclinical studies in which mTOR
 Thus, everolimus therapy may be able to ameliorate the negative
fects of mTOR inhibition on bone health during endocrine therapy.
enopausal women
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.  Introduction
Maintaining bone health is important for patients with
reast cancer because both the cancer itself and the therapies
sed to treat the disease can negatively affect bone. Bone
ealth challenges for patients with breast cancer commonly
tem from adjuvant endocrine therapy- and chemotherapy-
nduced bone loss in patients with early disease and disease
rogression in bone (i.e., bone metastases) in patients with
dvanced disease. Skeletal complications associated with
one metastases in patients with advanced disease can
e exacerbated by preexisting osteoporosis [1]. Following
urgical resection of the tumor, depending on the biol-
gy of the disease and risk of recurrence, patients with
reast cancer may require adjuvant chemotherapy and/or
ndocrine therapy. In particular, endocrine therapies used to
reat hormone-receptor-positive (HR+) breast cancer often
egatively impact bone health. In contrast with endocrine
herapies, the mammalian target of rapamycin [mTOR]
nhibitor, everolimus, appears to have a positive effect on
one in patients with advanced breast cancer [2].
Recently reported results from the phase 3 BOLERO-
 trial in postmenopausal women with HR+ breast cancer
rogressing despite nonsteroidal aromatase inhibitor (NSAI)
herapy showed significant clinical benefits with adding
verolimus to exemestane [3]. Notably, exploratory analy-
es from BOLERO-2 showed that adding everolimus also
ay have the beneficial effects of reducing bone turnover
nd breast cancer progression in bone in this patient pop-
lation [2]. The former observation in particular, although
xplained by preclinical data, may be potentially unexpected
hen combined with an endocrine-based treatment regimen.
his review will discuss how breast cancer, endocrine ther-
pies, and mTOR inhibition with everolimus influence bone
ealth.
.  Breast  cancer  and  bone
Breast cancer can influence the cells involved in bone
etabolism (i.e., osteoblasts and osteoclasts) in a manner
hat promotes cancer metastasis and growth and has adverse
ffects on bone health. Molecular signaling between bone
ells and breast cancer cells can lead to a destructive cycle
hat promotes the growth and dissemination of bone metas-
ases [4]. The release of growth factors (e.g., endothelin-1 and
ransforming growth factor-  family members) during bone
emodeling can stimulate proliferation of dormant breast can-
er cells [4]. This in turn promotes the development and
rogression of metastases. Furthermore, breast cancer cells
an secrete factors that also promote osteolysis, resulting
n a vicious cycle of tumor growth and bone destruction
4]. Because breast cancer preferentially metastasizes to the
keleton, bone metastases, a painful and potentially debil-
tating complication, develop in 65–75% of patients with
dvanced breast cancer [4,5]. As a result, maintaining bone
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ealth is of critical importance for patients with breast can-
er. Unfortunately, many anticancer therapies used to treat
he disease can adversely affect bone health.
Although a cornerstone for treating HR+ disease,
ndocrine therapies (especially aromatase inhibitors [AI])
sed to treat breast cancer are often detrimental to bone
ealth [6–13]. Estrogen is one of several local and systemic
actors that influence normal bone homeostasis, which is
aintained through continuous remodeling by osteoclasts
bone resorption) and osteoblasts (bone formation) [14].
ne mechanism through which estrogen acts on bone is
hrough the receptor activator of nuclear factor-kappa B
RANK)/osteoprotegerin pathway, wherein RANK ligand
RANKL) induces osteoclast activity and osteoprotegerin
cts as a physiologic inhibitor of RANKL [15–18]. Indeed,
reclinical studies have shown that suppression of estradiol
an reduce osteoprotegerin expression and increase RANKL
xpression [15,16,18,19]. Therefore, estrogen suppression
eads to increased osteoclast-mediated bone resorption in
esponse to elevated RANKL and decreased osteoprotegerin
evels.
Exploratory analyses from the NCIC MA.14 trial also sug-
est an increased risk of bone metastasis in patients with
igh bone resorption levels during adjuvant endocrine ther-
py [20]. These analyses examined the association of disease
ecurrence in bone only with serum beta C-terminal telopep-
ide of type I collagen (B-CTX). Of the 621 patients in the
riginal study, 123 had disease recurrence at 7.9 years median
ollow-up. Nineteen (3.1% of the 621) experienced bone-
nly recurrence and 47 (7.5% of the 621) had recurrence
n bone and other sites. In these patients, elevated pretreat-
ent serum B-CTX was associated with decreased bone-only
ecurrence-free survival (P  = .02). Although awaiting confir-
ation in other studies [21], these data support the concept
hat increased bone turnover fosters an environment ideal for
reast cancer metastasis and growth in some patient popula-
ions.
.  Effect  of  endocrine  therapies  on  bone
Much of the data regarding bone effects of endocrine ther-
pies derive from the adjuvant setting. Historically, tamoxifen
as the treatment of choice for endocrine-responsive breast
ancer and has been shown to preserve bone mineral density
n postmenopausal, but not premenopausal, women [22,23].
owever, fracture risks remained similar in postmenopausal
omen receiving tamoxifen compared with those who did not
eceive this therapy. Aromatase inhibitors (e.g., anastrozole,
etrozole, exemestane) are more effective anticancer agents
han tamoxifen and have largely replaced tamoxifen as the
reatment of choice for hormone-responsive breast cancer
n postmenopausal women [22,24–26]. Because AIs prevent
eripheral estrogen production, they suppress estrogen levels
eyond what happens during natural menopause. This activ-
ty is critical for treating hormone-responsive breast cancer
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activation of the mTOR signaling pathway also is asso-
ciated with endocrine resistance in breast cancer [41–45].
Everolimus, an oral inhibitor of mTOR, has been shown
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Fig. 1. Schematic illustration of mTOR/S6K intracellular signal transduc-
tion pathways in the osteoclast. M-CSF, TNF, and RANKL induced
signaling leading to activation of translation and inhibition of apoptosis. For
simplicity, TNF receptor and RANK are shown as one receptor. Abbre-
viations: AKT, protein kinase B; MAPK, mitogen-activated protein kinase;
mTOR, mammalian target of rapamycin; P, phosphate; RANKL, receptor
activator of nuclear factor-kappa B ligand; S6K; 40 S ribosomal S6 kinase;P. Hadji et al. / Critical Reviews in 
ut also leads to accelerated bone loss, which can compromise
one health [6,9–12,23].
Nonsteroidal aromatase inhibitors (i.e., letrozole, anas-
rozole) inhibit aromatase activity in a reversible manner,
nd are often the first type of hormonal therapy used in
atients with HR+ breast cancer. However, these agents have
een associated with bone loss occurring at more than twice
he rate of physiologic postmenopausal bone loss [7,27,28].
his leads to an increased risk of fractures [6,25,28,29],
otentially resulting in increased morbidity and mortality
30]. For example, analyses of the ATAC and MA.17 trials
howed that adjuvant anastrozole or letrozole was associated
ith increased bone turnover [7,27,28]. Overall, estrogen
epletion attained with NSAI therapy has been associated
ith reduced bone mineral density and elevated fracture risk
7,14,31–33].
The steroidal AI, exemestane, exerts irreversible effects
n aromatase activity and is often used to treat patients with
dvanced breast cancer whose disease progressed on NSAI
i.e., anastrozole and letrozole). However, a study in healthy
ostmenopausal women showed that the effects of exemes-
ane on bone markers are different from letrozole and anastro-
ole [9]. Furthermore, exemestane also has been associated
ith increased levels of bone resorption and bone formation
arkers [6,7,10]. In addition, several studies, including bone
ubstudies of the Tamoxifen Exemestane Adjuvant Multina-
ional (TEAM) trial, have shown that exemestane therapy is
ssociated with increased levels of bone resorption and bone
ormation markers [6,7,11,12,34,35]. Additionally, patients
n the TEAM study who received adjuvant exemestane also
ad a significantly higher fracture rate compared with those
ho received tamoxifen [35].
In contrast with AIs, fulvestrant, a selective estrogen
eceptor (ER) downregulator, has been shown to have min-
mal effects, neither positive nor negative, on bone health
36–38]. For example, serum bone-specific alkaline phos-
hatase (BSAP), N-terminal propeptide of procollagen type I
P1NP), and C-terminal telopeptide (CTX) levels were mea-
ured in a pilot study of 14 postmenopausal women with
dvanced breast cancer who derived clinical benefit with ful-
estrant (250 mg/month) [37]. The data indicate that there
ere no significant differences from baseline to any assessed
ime-point for BSAP, P1NP, or CTX levels. Changes in the
evels of these same bone markers also were evaluated in
 larger phase 2 study evaluating the adjuvant use of ful-
estrant 250 mg/month versus fulvestrant 500 mg/month in
ostmenopausal women with newly diagnosed breast can-
er (N  = 211) [38]. As with the small pilot study, there
ere no significant differences in bone marker levels at any
ime point compared with baseline or across treatment arms
38]. Together, these studies may suggest that, unlike other
ndocrine therapies, fulvestrant has a neutral effect on bone
ealth. However, as it is indicated for use after other endocrine
herapies, the neutral effects on bone might not be suffi-
ient for postmenopausal women who have lost bone mineral
ensity due to previous endocrine therapy.
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Everolimus, an mTOR inhibitor, is not an endocrine ther-
py. However, the mTOR pathway intersects with multiple
ndocrine signaling pathways in breast cancer cells. Crosstalk
an occur between the ER pathway and those of other growth
actors, leading to tumor progression as well as resistance
o endocrine therapy. Inhibition of the mTOR pathway with
verolimus may enhance sensitivity to endocrine therapy and
elay recurrence [39]. Indeed, this agent has been shown to
nhance the efficacy of endocrine therapy in patients with
R+ advanced breast cancer [3]. Furthermore, based on the
ellular functions influenced by the mTOR pathway, it is
ossible that everolimus may exert a protective effect on
one.
. Effect  of  everolimus  on  bone
The serine–threonine kinase, mTOR, regulates cell
rowth, angiogenesis, and cell survival [40]. However,rc, steroid receptor coactivator; TNF, tumor necrosis factor; TSC, tuberosis
clerosis complex.
eprinted by permission from Macmillan Publishers Ltd.: Cell Death Differ.
003;10:1165–1177, © 2003 [53].
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o enhance the efficacy of endocrine therapy (i.e., exemes-
ane) in postmenopausal women with HR+ advanced breast
ancer recurring or progressing during/after NSAI therapy
46,47]. Notably, based on analyses from the BOLERO-2
rial, everolimus was approved recently by the United States
ood and Drug Administration and the European Medicines
gency for use in this patient population [46,47].
.1.  PreclinicalResearch has demonstrated that there is crosstalk between
strogen-mediated and growth factor-mediated signaling
athways in breast cancer. For example, there is growing
c
s
t
ig. 2. mTOR inhibition decreases bone resorption, decreases osteoclast maturation
esorption by rapamycin. Rabbit bone marrow cells were seeded on bovine bone sli
t indicated concentrations. Release of collagen-I C-terminal telopeptides (CTX) int
ar is 100 M. (B) Osteoclastogenesis was assessed in the absence or presence of 
arrow/MB 1.8 cell coculture (day 7) and quantification of TRAP activity (right p
C) Purified osteoclasts were treated with rapamycin (100 nM) for 20 h. Immunofl
3342 (blue) together with FITC-phalloidin (green) to visualize nuclei and the act
ere traced (red) and superimposed for selected osteoclasts showing advanced ind
ype I collagen; mTOR, mammalian target of rapamycin; TRAP, tartrate-resistant a
eprinted by permission from Macmillan Publishers Ltd.: Cell Death Differ. 2003;gy/Hematology 87 (2013) 101–111
vidence supporting a close interaction between ER signaling
nd PI3K/Akt/mTOR signaling. The mTOR pathway is a
ey central regulator of cell growth and proliferation, and
TOR forms 2 different protein complexes, mTORC1 and
TORC2 [48]. The mTORC1 complex is responsible for
igand-independent activation of the ER [48]. Additionally,
stradiol can suppress the apoptosis induced by inhibi-
ion of PI3K/Akt/mTOR signaling [49]. Hyperactivation
f the PI3K/Akt/mTOR signaling pathway is an impor-
ant mediator of endocrine resistance in HR+ breast cancer
ells [42]. Furthermore, agents that inhibit PI3K/Akt/mTOR
ignaling have shown anticancer activity in endocrine resis-
ant breast cancer cell lines. For example, everolimus in
, and increases osteoclast apoptosis (mouse models). (A) Inhibition of bone
ces in 96-well plates and cultured in the absence or presence of rapamycin,
o the culture medium was measured after 72 h. Data are mean ± SD (n = 3);
rapamycin (30 nM, days 2–7). TRAP staining (left panels) of mouse bone
anel) by a fluorescent assay. Values are mean ± SD (n = 8); bar is 100 M.
uorescence image (overlay) of osteoclast nuclei stained with Hoechst No.
in cytoskeleton. Using corresponding phase-contrast images, cell outlines
uction of apoptosis. Bar is 100 M. Abbreviations: CTX, C-telopeptide of
cid phosphatase.
10:1165–1177, © 2003 [53].
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Fig. 3. The effects of everolimus on osteoblast differentiation (mouse
osteoblast cell line MC3T3). MC3T3 cells were cultured to confluency,
followed by induction of differentiation using an osteogenic stimulus. Treat-
ment with indicated concentrations of everolimus started at the beginning
of cultures. The results in the graph are means of two independent experi-
ments, each done in duplicate. The IC50 value was 13.5 nM. Abbreviation:
F
(
p
R
©P. Hadji et al. / Critical Reviews in 
ombination with letrozole has been shown to synergisti-
ally inhibit proliferation of estrogen-receptor-positive (ER+)
reast cancer cells [50]. Moreover, everolimus in combina-
ion with endocrine therapy also has been shown to reverse
esistance to endocrine therapy in ER+ breast cancer cell
ines expressing a constitutively active AKT protein (an
pstream activator of mTOR signaling and a potential media-
or of endocrine resistance) [51]. Notably, anticancer synergy
ith the combined use of mTOR and mevalonate pathway
nhibitors has been postulated in osteosarcoma, suggesting
hat mTOR inhibition also might have a positive impact on
isease burden in bone [52].
In addition to these anticancer effects, preclinical stud-
es suggest that mTOR inhibition may have other effects
n patients with breast cancer, most notably, a potential
eneficial effect on bone. In fact, preclinical evidence sug-
ests that mTOR signaling is involved in bone remodeling
52–58]. These effects are likely exerted via signal trans-
uction by cytokines through the mTOR pathway, which
ecreases osteoclast apoptosis and promotes osteoclast sur-
ival (Fig. 1) [53]. One cytokine pathway influenced by
TOR that is critical for osteoclast growth and differ-
ntiation is the RANK/osteoprotegerin pathway [53,56].
ALP, alkaline phosphatase.
Reprinted from Bone, 35, Kneissel M, et al., Everolimus suppresses cancel-
lous bone loss, bone resorption, and cathepsin K expression by osteoclasts,
1144–1156, © 2004, with permission from Elsevier [54].
ig. 4. Everolimus treatment decreased bone loss associated with estrogen deprivation (rat models). (Top row) CT images of the proximal tibia metaphysic;
Middle row) Osteoclast morphology on TRAP-stained 4-m microtome sections of the proximal tibia metaphysis (400×); (Bottom row) Bone mineralization
attern visualized by fluorochrome label uptake (alizarin red and calcein green) (200×). Abbreviation: OVX, ovariectomized.
eprinted from Bone, 35, Kneissel M, et al., Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts, 1144–1156,
 2004, with permission from Elsevier [54].
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Table 1
Beneficial bone effects of everolimus reported in the bone substudy of BOLERO-2.
Overall population (N = 724) EVE + EXE
n = 485
PBO + EXE
n = 239
EVE ↓ change in bone marker levels at 12 weeks relative to baseline P = .005, BSAP
P < .001, P1NP
P < .001, CTX
EVE ↓ progressive disease in bone P = .0363 (Gray’s test)
Patients with baseline bone metastases (N = 556) EVE + EXE
n = 371
PBO + EXE
n = 185
EVE ↓ change in bone marker levels at 12 weeks relative to baseline P = .001, BSAP
P < .001, P1NP
P < .001, CTX
EVE ↓ progressive disease in bone P = .0165 (Gray’s test)
Patients without baseline bone metastases (N = 168) EVE + EXE
n = 114
PBO + EXE
n = 54
EVE ↓ change in P1NP and CTX levels at 12 weeks relative to baseline P = 1.0, BSAP
P < .001, P1NP
P = .12, CTX
EVE ↓ progressive disease in bone Not reported
Patients with baseline bisphosphonate use (N = 342) EVE + EXE
n = 213
PBO + EXE
n = 129
EVE ↓ change in bone marker levels at 12 weeks relative to baseline P = .02, BSAP
P < .001, P1NP
P < .001, CTX
EVE ↓ progressive disease in bone Not reported
Patients without baseline bisphosphonate use (N = 382) EVE + EXE
n = 272
PBO + EXE
n = 110
EVE ↓ change in bone marker levels at 12 weeks relative to baseline P = .11, BSAP
P < .001, P1NP
P = .01, CTX
EVE ↓ progressive disease in bone Not reported
Data from Gnant et al. [2].
Abbreviations: BSAP, bone-specific alkaline phosphatase; CTX, C-terminal cross-linking telopeptide of type I collagen; EVE, everolimus; EXE, exemestane;
P1NP, amino-terminal propeptide of type I collagen; PBO, placebo.
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4n this signaling cascade, RANKL is a major determinant of
steoclast-mediated bone resorption, which is suppressed by
steoprotegerin, a physiological inhibitor of osteoclast func-
ion [59,60]. Notably, downregulating mTOR via suppression
f mTOR phosphorylation in the ST2 bone marrow-derived
tromal cell line has been shown to lead to upregulation of
steoprotegerin [56].
Other factors that reflect osteoclast activity may also
e influenced by mTOR inhibition. These include cathep-
in K, the main osteoclast-derived protease responsible for
igesting collagen type I in bone [54]. Cathepsin K mRNA
xpression and protein levels in human osteoclasts decreased
ubstantially after treatment with everolimus [54]. Evaluat-
ng CTX levels is an established measure of bone resorption
nd can be used as an indirect measure of the effect of mTOR
nhibition on bone. Notably, a study in cultured rabbit bone
arrow cells demonstrated that treatment with the mTOR
nhibitor rapamycin decreased production of CTX (Fig. 2A)
53]. Suppression of cathepsin K and CTX levels suggest that
TOR inhibition may lead to decreased bone resorption.
In addition to these indirect effects, animal models demon-
trate that inhibition of the mTOR pathway decreases bone
esorption [53,54]. For example, inhibiting mTOR in mice
t
iecreased osteoclast maturation (Fig. 2B) and increased
steoclast apoptosis (Fig. 2C) [53], suggesting that blocking
he mTOR pathway may lead to a protective effect on bone.
t is important to note that differentiation of osteoblasts,
one formation cells, also can be affected by mTOR inhi-
ition. In the MC3T3 mouse osteoblast cell line, everolimus
nhibited alkaline phosphatase, a marker of osteoblast differ-
ntiation, albeit only at higher concentrations (IC50 13.5 nM)
Fig. 3) [54]. Although everolimus inhibited differentiation
f both osteoclasts and osteoblasts in vitro, experiments
n ovariectomized rats showed that everolimus ameliorates
one loss associated with estrogen deprivation (Fig. 4) [54].
hese animal studies suggest that mTOR inhibition may exert
 bone-preserving effect. Together, these preclinical data
utline a potential mechanism by which everolimus could
meliorate the negative bone effects of endocrine therapy in
atients with advanced breast cancer.
.2.  ClinicalThe phase 3 BOLERO-2 trial demonstrated that the addi-
ion of everolimus to exemestane treatment significantly
mproved progression-free survival (PFS) in postmenopausal
P. Hadji et al. / Critical Reviews in Oncology/Hematology 87 (2013) 101–111 107
Table 2
Ongoing targeted agent studies evaluating bone markers as secondary endpoints.
Agent class Trial Patient population Treatment arms
TKI (Phase 2) Study 185 [64,68] HR+/HER2− advanced BC (planned N = 120);
<1 chemotherapy for metastatic disease or AI > 1 year
postadjuvant allowed
Dasatinib + LET vs LET alone
Study 261 [66,68] HR+ advanced BC after disease progression on NSAI
(planned N = 156)
Dasatinib + EXE vs placebo + EXE
Study 158 [65,68] HR+ advanced BC previously treated with AI (planned
N = 100)
Dasatinib + FUL vs FUL alone
Study 11–208 [69] HR+ advanced BC with bone metastases Cabozantinib (open-label, single arm)
Pan-PI3K (Phase 3) BELLE-2 [71] HR+/HER2− advanced BC after disease progression on
AI (planned N = 842)
BKM120 + FUL vs placebo + FUL
BELLE-3 [70] HR+/HER2− advanced BC after disease progression on
endocrine therapy + everolimus (planned N = 615)
BKM120 + FUL vs placebo + FUL
mTOR (Phase 3) BOLERO-1 [67] HER2+ advanced BC (planned N = 717) Everolimus + trastuzumab + PAC vs
placebo + trastuzumab + PAC
BOLERO-2 [3] HR+/HER2− advanced BC after disease progression on
NSAI (N = 724)
Everolimus + EXE vs placebo + EXE
Abbreviations: AI, aromatase inhibitor; BC, breast cancer; EXE, exemestane; FU, fulvestrant; LET, letrozole; mTOR, mammalian target of rapamycin; NSAI,
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omen with HR+ advanced breast cancer progressing on
rior NSAI therapy [3]. In addition to the positive PFS results
f the overall trial, everolimus also may have a positive effect
n bone health in this patient population.
Although other clinical studies of mTOR inhibitors in
atients with breast cancer have reported results, these did
ot include any bone-specific endpoints [61,62]. In contrast,
xploratory analyses in BOLERO-2 evaluated the effect of
verolimus on bone marker levels and progressive disease in
one (Table 1) [2]. Bone marker data suggest that everolimus
uppresses bone turnover and reverses the increases in bone
esorption associated with both progressive disease in bone
nd effects of exemestane treatment on normal bone turnover.
dding everolimus to exemestane therapy also reduced the
ncidence of breast cancer progression in bone (i.e., appear-
nce of new bone metastases or progression of preexisting
one metastases) in the overall patient population (N  = 724;
 = .04, Gray’s test) [2]. Furthermore, the reduction of pro-
ressive disease in bone also was significantly lower in the
ubset of patients with bone metastases at baseline (n  = 556;
 = .02, Gray’s test). Positive bone effects with everolimus
ere in addition to the reported improvements in PFS, clinical
enefit rate, and quality of life with everolimus [63].
In addition to reducing disease progression in bone,
verolimus might help protect bone health. In BOLERO-
, a marked increase in osteoclast metabolism (i.e., BSAP),
one formation (i.e., P1NP), and bone resorption (i.e., CTX)
arker levels was observed in the placebo plus exemestane
rm at weeks 6 and 12 relative to baseline [2]. In contrast,
here was a significant decrease in these same bone marker
evels with everolimus plus exemestane at weeks 6 (26.4%
or BSAP, 55.9% for P1NP, and 35.9% for CTX; P  < .001 for
ll) and 12 (20.3% for BSAP, 66.2% for P1NP, and 40.5%
or CTX; P  ≤  .005 for all) relative to baseline. Furthermore,
hese effects were not influenced by baseline bisphosphonate
s
o
ese or the presence of bone metastases at baseline (Table 1)
2]. The elevated bone marker levels reported in the placebo
lus exemestane arm suggests that the rates of bone turnover
re higher with exemestane therapy alone. This may be con-
istent with prior reports in postmenopausal women receiving
djuvant exemestane therapy for breast cancer [6,9–12].
verall, the results of the BOLERO-2 exploratory analyses
uggest that everolimus may protect bone health, potentially
ompensating for the negative bone effects associated with
xemestane therapy.
. Conclusions
In contrast with AIs and fulvestrant, everolimus may have
eneficial effects on bone metabolism, potentially reduc-
ng bone resorption and contributing to a bone-protective
ffect. This benefit might be particularly relevant to post-
enopausal women who have previously received NSAIs for
 long period, and therefore may have experienced substantial
one loss. Preclinical evidence indicates that mTOR inhibi-
ion reduces osteoclast differentiation and survival and shows
hat treatment with everolimus ameliorates bone loss due to
strogen deprivation in rat models. These findings provide
upport for the beneficial bone effects of everolimus observed
n the BOLERO-2 study. The observed reduction of pro-
ressive disease in bone with everolimus, including delaying
rogression of existing bone lesions, could be the net result
f several mechanisms: anticancer effect on bone metastases
onsistent with the overall significant improvement in PFS,
irect effects of mTOR inhibition on osteoclast survival and
ubsequent bone resorption, or a combination of these and
ther as yet undetermined mechanisms [53,54,57,59,60].
The potential benefits of mTOR inhibition with
verolimus are of great clinical importance. For example,
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tilizing everolimus therapy to reduce bone turnover in
atients receiving endocrine therapy for advanced breast can-
er may help patients maintain bone mineral density, thereby
voiding osteoporotic fractures and maintaining quality of
ife. Additionally, the protective effects of everolimus on
one differentiate this agent from endocrine therapies for
R+ breast cancer, as some of these (particularly AIs) have
 negative effect on bone. Although the data are compelling,
 definite clinical benefit cannot be established solely on the
asis of these exploratory analyses, and insights from clin-
cal trials of everolimus in the adjuvant setting are awaited.
otably, the ability of targeted therapies, especially kinase
nhibitors, to alter osteoclast survival and function is the
ubject of substantial clinical research. Ongoing studies are
nvestigating potential bone-directed effects of several tar-
eted agents in advanced breast cancer (Table 2) [3,64–71],
nd results from these studies may provide additional avenues
or preserving bone health in addition to achieving disease
ontrol in postmenopausal women with advanced breast can-
er.
These data also suggest that earlier (adjuvant) use
f everolimus may be beneficial to postmenopausal
omen with ER+ breast cancer. Potential adjuvant bene-
ts with everolimus may derive from overcoming endocrine
esistance and restoring/enhancing endocrine sensitivity,
specially in patients at high risk for breast cancer recur-
ence during standard adjuvant endocrine therapy (e.g., based
n prognostic factors and multigene risk scores). Currently,
everal adjuvant trial protocols are being developed and dis-
ussed by the global investigator community to evaluate
he potential role of adjuvant everolimus in postmenopausal
omen with ER+ breast cancer [72,73].
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